HNSCC Subtyping via Gene Expression Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for classifying head and neck squamous cell carcinoma (HNSCC) tumors are inadequate for predicting treatment response and patient management, as they do not effectively utilize underlying genomic and biologic tumor characteristics.
Innovation Solution
A method for determining HNSCC subtypes by evaluating gene expression levels of specific classifier biomarkers, which categorizes tumors into four subtypes (Atypical, Mesenchymal, Classical, and Basal) using an algorithm, optionally including nodal status evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current classification methods are used for HNSCC tumors, then the classification process is simple, but the ability to predict treatment response and patient management is inadequate
Solution Approach 1:
The patent segments HNSCC tumors into four distinct molecular subtypes (basal, mesenchymal, classical, and atypical) based on gene expression profiles. This segmentation allows for more precise treatment response prediction by categorizing tumors according to their underlying genomic and biologic characteristics rather than using a single uniform classification approach.
Solution Approach 2:
The patent changes the classification parameters from traditional clinical-pathological criteria to molecular gene expression parameters. By measuring and analyzing the expression levels of specific genes, the system transforms the classification basis to include genomic information, thereby improving treatment response prediction while incorporating more sophisticated measurement techniques.
2Loss of information
If traditional classification approaches are used, then the diagnostic process is straightforward, but underlying genomic and biologic tumor characteristics are not effectively utilized
Solution Approach 1:
The patent replaces traditional mechanical/pathological examination methods with molecular biology techniques for detecting gene expression. By using gene expression profiling assays, the system substitutes conventional diagnostic approaches with methods that can effectively capture and analyze genomic and biologic tumor characteristics.
Solution Approach 2:
The patent introduces gene expression profiles as an intermediary between traditional pathology and treatment decision-making. These molecular characteristics serve as mediators that bridge the gap between tumor biology and clinical management, enabling more informed treatment selection while systematically utilizing genomic information.
Data Source
AI summary
Methods, systems and compositions are provided for determining a subtype of head and neck squamous cell carcinoma (HNSCC) of an individual by detecting the expression level of a plurality of classifier biomarkers selected from a gene signature for HNSCC presented herein. Also provided herein are methods and compositions for determining the response of an individual with a HNSCC subtype to a therapy such as radiation therapy.